ILB-202
/ ILIAS Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 26, 2025
Safety and Anti-Inflammatory Effects of Engineered Extracellular Vesicles (ILB-202) for NF-κB Inhibition: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial.
(PubMed, J Extracell Vesicles)
- P1 | "Single-cell RNA sequencing revealed subtle, time-dependent modulation of NF-κB-associated pathways, enhanced TGF-β and visfatin signalling and reduced TNF signalling-suggesting a shift towards an anti-inflammatory state. These findings support the safety and immunomodulatory activity of ILB-202 and pave the way for future trials in diseases characterized by dysregulated NF-κB activation. Trial Registration: ClinicalTrials.gov identifier: NCT05843799."
Clinical • Journal • P1 data • Hematological Disorders • Immunology • Inflammation • Neutropenia • NAMPT • NFKBIA • TGFB1
September 11, 2023
A Study to Evaluate the Safety and Tolerability of ILB-202
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: ILIAS Biologics Inc. | Recruiting ➔ Completed
Trial completion
May 31, 2023
A Study to Evaluate the Safety and Tolerability of ILB-202
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: ILIAS Biologics Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
May 06, 2023
A Study to Evaluate the Safety and Tolerability of ILB-202
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: ILIAS Biologics Inc.
New P1 trial
1 to 4
Of
4
Go to page
1